Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doc Bones who wrote (7768)	1/20/2003 5:55:04 PM
From: Miljenko Zuanic	Read Replies (2) of 52153

First one to emerge with fresh data on late stage trial is ALT. However, timing of the cc suggest (to me) that data are mixed. Press Release Source: Alteon Inc. Alteon Inc. Announces Investor Update Conference Call Tuesday, January 21, 2003, 2:00 P.M. Eastern Time Monday January 20, 12:58 pm ET RAMSEY, N.J., Jan. 20 /PRNewswire-FirstCall/ -- Alteon Inc. (Amex: ALT - News) announced today that it will hold an investor update conference call on Tuesday, January 21, 2003 at 2:00 p.m. eastern time which will include a discussion of preliminary results of the Phase IIa DIAMOND trial of ALT-711 in diastolic heart failure. <snip>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next